MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks InsideIn today’s MAGA Stocks Undercard lineup, a select group of small-cap innovators are reshaping the landscapes of social media, biotech, and blockchain technology. These companies—each positioned at the forefront of next-generation disruption—are demonstrating renewed investor confidence and sector-wide momentum heading into Q4.
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentReid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentDr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial ResultsEstablishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsExpanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformResearch and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsEncouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (
NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology ProgramCollaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications
